Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40012689
Localisation
China
Asia
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
21/08/2025
Statut
Classification
1.5°C
Année cible
2034
Statut
Targets set
Classification
1.5°C
Année cible
2050
Overall Net-Zero Target: WuXi Biologics (Cayman) Inc. commits to reach net-zero greenhouse gas emissions across the value chain by 2050. Near-Term Targets: WuXi Biologics (Cayman) Inc. commits to reduce absolute scope 1 and 2 GHG emissions 58.8% by 2034 from a 2024 base year. WuXi Biologics (Cayman) Inc. also commits to reduce scope 3 GHG emissions covering purchased goods and services 63.8% per kg of product produced within the same timeframe. Long-Term Targets: WuXi Biologics (Cayman) Inc. commits to reduce absolute scope 1 and 2 GHG emissions 90% by 2050 from a 2024 base year. WuXi Biologics (Cayman) Inc. also commits to reduce absolute scope 3 GHG emissions covering purchased goods and services, capital goods, fuel and energy related activities, upstream transportation and distribution, waste generated in operations and employee commuting 90% within the same timeframe.
Statut
Targets setAnnée cible
2050
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
ISIN
KYG970081173
Source : Science Based Targets initiative | Données publiques